**NOR IDS Evaluation Planning Matrix**

**Questions in Blue Text** were identified as priorities by NOR leadership

|  |  |  |
| --- | --- | --- |
| **Category** | **Question** | **Data Source** |
| **1. Planning** | How and why did IDS systems decide to prioritize HPV vaccination and participate in the project? | IDS staff survey/interview |
| **1. Planning** | What role did ACS play in the IDS deciding to prioritize and participate? | IDS staff survey/interview |
| 1. **Planning** | How effective were the action guides as a framework for recruiting IDS partners? | ACS staff survey  IDS staff survey/interview |
| **2. Activities** | How did IDS approve, prioritize, disseminate EBIs? | IDS staff survey/interview  CAP |
| **2. Activities** | What role did ACS staff play in implementing project activities? | ACS staff survey  CAP |
| **2. Activities** | What was the value-add of ACS to the IDS HPV vaccination efforts? | IDS staff survey/interview |
| **2. Activities** | How were the action guides used to train and/or educate IDS staff? Which guides were used? | IDS staff survey/interview |
| Did the IDS use any of the supporting training resources (ppts, handouts, graphics)? How valuable were these resources? |
| Are the actions in the guides being implemented in the IDS? If so, how? |
| **3. Outputs** | How many IDS and clinics participated in the project, and what was their target patient population? | CAP |
| **3. Outputs** | How many IDS providers and staff were trained on HPV vaccination as part of the project? | CAP |
| **3. Outputs** | Which ACS, RT, and CDC tools and resources were used? | CAP |
| **3. Outputs** | In achieving your strategies/goals, how useful and effective were each of the action guides? Training tools and resources?  How could they be improved? | IDS staff survey/Interview |
| **3. Outputs** | Which EBIs were implemented? | CAP |
| **3. Outputs** | How useful and effective were each of the EBIs? | IDS staff survey/Interview |
| **4. Outcomes** | How did HPV and other adolescent vaccination rates change over the course of the project? | CAP |
| **4. Outcomes** | Did the IDS evaluate a change in knowledge and behaviors of staff as a result of the action guides/action guide training? If so, is the IDS willing to share deidentified findings with the HPV Roundtable? | IDS staff survey/Interview |
| **4. Outcomes** | How many IDS met the vaccination rate improvement goals in their AIM statements? | CAP |
| **4. Outcomes** | If they did not meet the vaccination rates, why not? What were the challenges/barriers/setbacks? | IDS staff Survey/Interview |
| **5. Facilitators & Barriers** | What strategies and factors contributed to success? | IDS staff survey/interview  ACS staff survey |
| **5. Facilitators & Barriers** | What challenges were experienced during the project? | IDS staff survey/interview  ACS staff survey |
| **5. Facilitators & Barriers** | What were the strengths and weaknesses of the Large Systems Action Guide and CAP as the primary project tools? | IDS staff survey/interview  ACS staff survey |
| **5. Facilitators & Barriers** | Would IDS recommend to other colleagues/practices?  Have IDS staff shared the tool with anyone else? | IDS staff survey/Interview |
| **6. IDS dynamics** | Describe your QI infrastructure prior to the pilot project. (organizational levels, any immunization QI)  To what extent was this type of centralized QI effort new to IDS systems? Has it changed practices beyond this project? | IDS staff survey/interview |
| **6. IDS dynamics** | What impact did the project have on IDS staff engagement and buy-in to the QI process in general? | IDS staff survey/interview |
| **6. IDS dynamics** | How was this project different than other IDS QI efforts? | IDS staff survey/interview |
| **6. IDS dynamics** | Who were the key HPV initiative champions in the system? | IDS staff survey/interview |
| **6. IDS dynamics** | What was the engagement of the C Suite leadership in supporting the initiative? | IDS staff survey/interview |
| **7. ACS dynamics** | How was this project different from ACS HPV vaccination QI efforts with FQHC partners? | Infer from other questions |
| **7. ACS dynamics** | How did this project influence ACS Hospital Systems work at large? | All HS staff survey  ACS staff survey  Leadership team survey |
| **7. ACS dynamics** | What were the strengths and weaknesses of a project model involving collaboration among a Region, VACs, and a RT working group? | Leadership team survey |

**Data Sources**

|  |  |  |
| --- | --- | --- |
| **Data Source** | **Description** | **Collection Frequency** |
| **Collaborative Action Plan (CAP)** | Primary project data collection and planning tool. Includes general system data, prior activities, planned activities, implemented activities, and baseline, midpoint, and follow-up vaccination rates. | Baseline (July-Sept 2018)  Midpoint (Jan-Feb 2019)  Follow-up (July-Aug 2019) |
| **IDS staff survey and/or interview (TBD)** | Details TBD – to answer many of the evaluation questions that require nuanced IDS perspective, we will need some way to collect data from IDS staff partners. Could include a survey, interviews, or both. Participants should include IDS project leads and champions, and perhaps participating providers. | Project completion (July-Aug 2019) |
| **ACS staff survey** | To answer evaluation questions that require nuanced perspective from ACS Hospital Systems staff implementing the project | Project completion (July-Aug 2019) |
| **Leadership team survey** | To answer evaluation questions that require nuanced perspective from NOR Hospital Systems leadership, VACs team, and RT team | Project completion (July-Aug 2019) |